Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
PURITAN MEDICAL
RANDOX LABORATORIES

Beryllium Causes Deadly Lung Disease

By Labmedica International staff writers
Posted on 17 Jul 2014
Image: Histology of lung tissue from a chronic beryllium disease patient showing granulomatous tissue (Photo courtesy of the Cleveland Clinic).
Image: Histology of lung tissue from a chronic beryllium disease patient showing granulomatous tissue (Photo courtesy of the Cleveland Clinic).
How the metal beryllium triggers a deadly immune response in the lungs has been discovered using detailed maps of molecular shapes and the electrical charges surrounding them.

A genetic susceptibility to the disease creates a molecular pocket in an immune system protein, which captures beryllium ions and triggers an inflammatory response in the lungs and this immune response lies somewhere between classic forms of allergic hypersensitivity and autoimmunity.

Scientists at the Howard Hughes Medical Institute (Denver, CO, USA) performed a series of highly detailed genetic, X-ray diffraction, molecular binding and electrostatic studies to show how this single amino acid can combine with other amino acids from the human leukocyte antigen (HLA)-DP2 subunit and some of its bound self-peptides to create a unique molecular pocket that captures a single beryllium ion along with a sodium ion.

The peptides that bind to HLA-DP2 come from the body's own tissues and normally elicit no immune response. With the beryllium and sodium firmly lodged in the molecular pocket, however, those peptides have a very slightly altered shape and electrical charge, which roving T cells recognize as foreign and dangerous. They initiate an immune response that causes inflammation and scarring in the lungs. The thermal stabilities of various major histocompatibility complex (MCH) alleles, the MHCII-peptide complexes, were determined by differential scanning fluorimetry using either a Stratagene MX3005p (Agilent; Santa Clara, CA, USA) or CFX96 real time polymerase chain reaction instrument (RCT-PCR, Bio-Rad; Hercules, CA, USA).

About 85% of people who develop chronic beryllium disease have the immune system protein HLA-DP2. Cells throughout the body use this molecule to tell the immune system what is going on inside of them. HLA-DP2 sits on the cell surface holding small protein fragments taken from the cell's interior. Immune system sentinels known as T cells collide against HLA-DP2 and its displayed protein fragment. If the protein fragment is derived from the body's own proteins, the T cell ignores it; if it is a foreign peptide, say from a bacterium, virus or other pathogen, the T cell sounds the alarm and triggers an immune response.

John W. Kappler, PhD, a professor of immunology and the senior author of the study said, “This response resembles allergic hypersensitivity in that a metal ion causes an allergic reaction. But it also resembles autoimmunity in that the immune system is mounting an attack against a self-peptide. It is a new form of immune response, and may lead to new therapeutic strategies to treat and prevent the disease.” The study was published on July 3, 2014, in the journal Cell.

Related Links:

Howard Hughes Medical Institute 
Agilent
Bio-Rad



KARL HECHT GMBH & CO KG
DIASYS DIAGNOSTIC SYSTEMS
Dubai Bio Expo-2015

Channels

Genetic Tests

view channel
Image: The final result of a DNA sequencing process, with each color representing one of the four base chemicals, adenine, guanine, cytosine and thymine, that comprise DNA (Photo courtesy of Gerald Barber).

Gene Sequencing Reference Standard Increases Accuracy for Medical Laboratories

To reduce the variability in genetic test results that has been observed across different clinical laboratories and pathology groups, a new standard DNA reference has been introduced, which will improve... Read more

Hematology

view channel
Image: Immunochemistry of bone marrow biopsy from an acute myeloid leukemia patient showing sheets of CD34 positive cells; corresponding bone marrow aspirate showed only 20% blasts (Photo courtesy of All India Institute of Medical Sciences).

Immunohistochemistry Assesses Early Response in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a heterogeneous disease with respect to prognosis and early response assessment has an established role as predictor of remission rate, and overall and disease-free survival.... Read more

Industry News

view channel

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer. The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.